After Needham and Ladenburg gave Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Phil Nadeau maintained a Buy rating on Rhythm Pharmaceuticals Inc today and set a price target of $40. The company’s shares opened today at $25.57, close to its 52-week low of $23.25.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.6% and a 50.1% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Phasebio Pharmaceuticals Inc, and Rocket Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $39.75, which is a 55.5% upside from current levels. In a report released today, Ladenburg also maintained a Buy rating on the stock with a $43 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $37.23 and a one-year low of $23.25. Currently, Rhythm Pharmaceuticals Inc has an average volume of 76.62K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RYTM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rhythm Pharmaceuticals, Inc. develops and commercializes peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity.
